ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Anette Mertens contributed 17 entries already.
Synairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. The funding will advance the Phase 2 INVENT trial, assessing SNG001, an inhaled formulation of the antiviral protein interferon beta, in mechanically ventilated patients with severe viral lung infections.
Johnson & Johnson has announced the acquisition of biopharmaceutical company Intra-Cellular Therapies, strengthening its position in the market for central nervous system disorder treatments. The $14.6 billion deal involves J&J paying $132 per share, representing a 39% premium over Intra-Cellular’s last closing price.
Leyden Labs has raised $70 million in a funding round led by ClavystBio and Polaris Partners, boosting its efforts to develop intranasal antibody therapies targeting respiratory viruses, including influenza and coronaviruses.
Angelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna Therapeutics, accelerating next-generation RNA therapeutics for epilepsy and neurological diseases.
Inverna Therapeutics, a Danish biotech company, has officially launched to develop innovative RNA-based therapies targeting severe genetic diseases. Co-founded by the University of Southern Denmark and Argobio, Inverna will focus on its lead programme addressing Huntington’s disease.
WuXi Biologics has agreed to sell its Dundalk vaccine manufacturing facility to Merck, a move that will enhance asset efficiencies and allow the company to focus on CDMO services at its other global sites.
Orbis Medicines secures €90m in Series A funding to accelerate the development of oral macrocycle drugs, leveraging automated chemistry and machine learning.
LAB Automation – The Society for Laboratory Automation and Screening (SLAS) is transforming the global life sciences community by uniting interdisciplinary researchers and technology providers to drive innovation in laboratory automation and research.
Dewpoint Therapeutics Inc and Mitsubishi Tanabe Pharma Corporation have formed a collaboration, valued at up to $480m, to develop a novel small molecule condensate modulator for ALS, leveraging groundbreaking European research in condensate biology.
The Society for Laboratory Automation and Screening (SLAS) is transforming the global life sciences community by uniting interdisciplinary researchers and technology providers to drive innovation in laboratory automation and research.